Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients

Diabetes. 1995 Nov;44(11):1318-22. doi: 10.2337/diab.44.11.1318.

Abstract

To investigate the effects of insulin on platelets in obesity and in non-insulin-dependent diabetes mellitus (NIDDM)--classic insulin-resistant states--we determined ADP-induced platelet aggregation and platelet cGMP (guanosine 3',5'-cyclic monophosphate) content in platelet-rich plasma obtained from nine obese subjects and nine age-matched healthy volunteers and from eight NIDDM obese patients and nine age-matched healthy volunteers after a 3-min incubation with human recombinant insulin (0, 240, 480, 960, and 1,920 pmol/l). Platelet aggregation was evaluated using different ADP doses to measure the ADP concentration determined on the basis of a dose-response curve necessary to elicit a maximal aggregation of 50% (ED50). Insulin induced a dose-dependent decrease of platelet aggregation to ADP (P = 0.0001) in healthy subjects. A significant effect was evident starting from an insulin concentration of 240 pmol/l. On the contrary, in insulin-resistant subjects, insulin reduced platelet sensitivity to ADP only at a concentration of 1,920 pmol/l. When ADP ED50 values obtained in platelet-rich plasma incubated with insulin were expressed in percentage of the ADP ED50 values obtained in platelet-rich plasma without insulin, considered as 100%, we observed that ADP ED50 with 1,920 pmol/l insulin was 153.6 +/- 13.2% in the younger healthy subject group (P = 0.004), 150.0 +/- 3.8% in the older healthy subject group (P = 0.0001), 116.1 +/- 6.1% in obese subjects (P = 0.031), and 120.0 +/- 8.6% in NIDDM patients (P = 0.05). In healthy subjects, insulin induced a dose-dependent increase of platelet cGMP (P = 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Diphosphate / pharmacology
  • Adult
  • Blood Platelets / drug effects
  • Blood Platelets / physiology*
  • Blood Pressure
  • Case-Control Studies
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Diabetes Mellitus / blood*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Dose-Response Relationship, Drug
  • Female
  • Glycated Hemoglobin / analysis
  • Humans
  • In Vitro Techniques
  • Insulin / blood
  • Insulin / pharmacology*
  • Male
  • Obesity / blood*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Recombinant Proteins / pharmacology
  • Reference Values
  • Triglycerides / blood

Substances

  • Cholesterol, HDL
  • Glycated Hemoglobin A
  • Insulin
  • Platelet Aggregation Inhibitors
  • Recombinant Proteins
  • Triglycerides
  • Adenosine Diphosphate
  • Cholesterol